|
Diagnostic BI-RADS findings in single-side breast on mammography and/or ultrasound
|
|
Breast with lesion (cancer/benign)
|
BI-RADS 4
|
11 (22 %)
|
47 (92 %)
|
|
BI-RADS 5
|
40 (78 %)
|
4 (8 %)
|
|
Contralateral (studied) breast
|
BI-RADS 1
|
27 (53 %)
|
21 (41 %)
|
|
BI-RADS 2
|
19 (37 %)
|
25 (49 %)
|
|
BI-RADS 3
|
1 (2 %)
|
1 (2 %)
|
|
BI-RADS 4
|
4 (8 %)
|
4 (8 %)
|
|
BI-RADS 5
|
0 (0 %)
|
0 (0 %)
|
|
Age, years, mean ± SD (range)
|
47.6 ± 7.4 (34–60)
|
47.1 ± 7.3 (31–60)
|
|
Menopausal status
|
|
Premenopausal
|
28 (55 %)
|
30 (59 %)
|
|
Postmenopausal
|
23 (45 %)
|
21 (41 %)
|
|
Known pathogenic BRCA1/2 mutation
|
2 (4 %)
|
0 (0 %)
|
|
History of prior breast cancer
|
0 (0 %)
|
0 (0 %)
|
|
Family history of breast cancer
|
26 (51 %)
|
31 (61 %)
|
|
Family history of ovarian cancer
|
3 (6 %)
|
0 (0 %)
|
|
Prior biopsy (>1 year prior to the studied biopsy)
|
|
Atypia
|
1 (2 %)
|
0 (0 %)
|
|
Benign abnormality
|
9 (18 %)
|
6 (12 %)
|
|
Exogenous hormone use
|
|
Hormone replacement therapy
|
7 (14 %)
|
5 (10 %)
|
|
Birth control pills
|
33 (65 %)
|
34 (67 %)
|
|
Tamoxifen
|
1 (2 %)
|
0 (0 %)
|
|
None
|
5 (10 %)
|
12 (24 %)
|
|
Oophorectomy
|
0 (0 %)
|
0 (0 %)
|
|
Mammographic density (visual BI-RADS density description)
|
|
Fatty
|
2 (4 %)
|
1 (2 %)
|
|
Scattered fibroglandular density
|
14 (27 %)
|
13 (25 %)
|
|
Heterogeneously dense
|
32 (63 %)
|
33 (65 %)
|
|
Extremely dense
|
3 (6 %)
|
4 (8 %)
|
|
Background parenchymal enhancement, BPE%, mean ± SD (range)
|
44.6 ± 8.9 (20.9–62.0)
|
39.8 ± 11.4 (17.9–61.6)
|
|
Kinetics imaging measures, mean ± SD (range)
|
|
Wash-in slope variance × 100 (unit)
|
2.90 ± 2.72 (0.48–15.42)
|
1.75 ± 1.26 (0.43–6.87)
|
|
Signal enhancement ratio volume, cm3
|
118.9 ± 85.6 (26.1–429.8)
|
80.4 ± 42.9 (21.1–194.5)
|
